BETHANECHOL CHLORIDE
Clinical safety rating: safe
Animal studies have demonstrated safety
Bethanechol chloride is a direct-acting cholinergic agonist that stimulates muscarinic acetylcholine receptors, primarily M2 and M3 subtypes, leading to increased smooth muscle tone and secretions in the gastrointestinal and genitourinary tracts.
| Metabolism | Primarily metabolized via hydrolysis by cholinesterases; also undergoes partial hepatic metabolism. |
| Excretion | Primarily renal excretion of unchanged drug via glomerular filtration and active tubular secretion. Approximately 80-90% of a subcutaneous dose is recovered unchanged in urine within 24 hours; minimal biliary or fecal elimination (<5%). |
| Half-life | Terminal elimination half-life is approximately 1.5-2 hours. Clinical context: short half-life necessitates dosing every 6-8 hours for sustained effect; accumulation unlikely with normal renal function. |
| Protein binding | Minimal to negligible (<5%). Theoretical binding potential with albumin but clinically insignificant. |
| Volume of Distribution | Approximately 0.5-1.0 L/kg. Moderate Vd indicates distribution into total body water and extracellular fluid; does not cross blood-brain barrier. |
| Bioavailability | Oral: approximately 10-20% due to extensive presystemic metabolism (hydrolysis by cholinesterases and hepatic first-pass effect). Subcutaneous: virtually 100%. |
| Onset of Action | Oral: 30-90 minutes. Subcutaneous: 5-15 minutes. Note: due to poor oral bioavailability, subcutaneous route is preferred for predictable onset. |
| Duration of Action | Oral: 4-6 hours. Subcutaneous: 2-4 hours. Clinical notes: effects may persist longer in patients with impaired renal function; tolerance may develop with prolonged use. |
10-50 mg orally 2-4 times daily. Alternatively, 2.5-5 mg subcutaneously 3-4 times daily.
| Dosage form | TABLET |
| Renal impairment | Contraindicated in patients with GFR < 50 mL/min. No dose adjustment defined for mild impairment. |
| Liver impairment | No specific adjustment for hepatic impairment. Use with caution in severe liver disease due to potential for increased systemic effects. |
| Pediatric use | Safety and efficacy in children < 8 years not established. For older children, 0.3-0.6 mg/kg/day orally in 3-4 divided doses. |
| Geriatric use | Initiate at lower end of dosing range (e.g., 10 mg orally 2-3 times daily) due to increased risk of hypotension and falls. Monitor closely for cholinergic excess. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Other cholinergic agents can have additive effects Bethanechol is contraindicated in conditions where increased muscular activity of the GI tract or bladder might be harmful.
| Breastfeeding | Bethanechol is excreted into breast milk in small amounts due to its quaternary structure and low lipid solubility. The M/P ratio is not established. Limited data suggest no adverse effects in breastfed infants, but caution is advised. Monitor infant for cholinergic effects (diarrhea, salivation, bradycardia). |
| Teratogenic Risk | Bethanechol is a quaternary ammonium compound with limited systemic absorption; no adequate human studies exist. In animal studies, no teratogenic effects were observed at clinically relevant doses. However, as with all drugs, use during pregnancy only if clearly needed. Theoretical risk of inducing uterine contractions, especially in third trimester, may lead to fetal distress or preterm labor. |
■ FDA Black Box Warning
None.
| Common Effects | Abdominal cramps |
| Serious Effects |
["Hypersensitivity to bethanechol or any component of the formulation","Hyperthyroidism","Peptic ulcer disease","Asthma or bronchial asthma","Bradycardia or hypotension","Coronary artery disease or myocardial ischemia","Epilepsy or Parkinsonism","Gastrointestinal or genitourinary obstruction","Peritonitis or recent bladder surgery","Mechanical obstruction of the gastrointestinal or urinary tract"]
| Precautions | ["May cause bronchoconstriction; use with caution in patients with asthma or COPD.","Can induce hypotension, reflex tachycardia, and bradycardia.","May cause gastrointestinal distress including diarrhea, abdominal cramps, nausea, and vomiting.","Use cautiously in patients with hyperthyroidism, peptic ulcer disease, epilepsy, Parkinsonism, or cardiovascular disease.","May cause excessive salivation, sweating, and flushing."] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of cholinergic excess (bradycardia, hypotension, bronchoconstriction, increased gastrointestinal motility) in mother and fetus. Fetal heart rate monitoring during administration in third trimester. Assess for uterine activity if used near term. No specific fetal monitoring required for standard use. |
| Fertility Effects | No known effects on human fertility. Animal studies have not demonstrated impaired fertility. The drug's cholinergic action may theoretically affect uterine receptivity, but no data support clinical significance. |
| Food/Dietary |
| No specific food interactions reported. However, taking with food may reduce drug absorption and increase gastrointestinal adverse effects. Avoid excessive alcohol consumption, which may worsen side effects. |
| Clinical Pearls | Administer on an empty stomach (1 hour before or 2 hours after meals) to avoid nausea and vomiting. Contraindicated in mechanical GI or GU obstruction, asthma, hyperthyroidism, peptic ulcer disease, epilepsy, parkinsonism, bradycardia, hypotension, and recent bladder or GI surgery. Have atropine sulfate available as an antidote. Start with low doses and titrate based on response. Monitor for signs of cholinergic excess: salivation, sweating, abdominal cramps, diarrhea, bronchospasm, bradycardia. Subcutaneous route is preferred for rapid onset; avoid intramuscular or intravenous due to risk of severe cholinergic reactions. |
| Patient Advice | Take this medication on an empty stomach, at least 1 hour before or 2 hours after meals, to prevent stomach upset. · Do not crush or chew tablets; swallow whole with a glass of water. · Report any signs of overdose such as excessive sweating, salivation, nausea, vomiting, diarrhea, abdominal cramps, slow heartbeat, or difficulty breathing immediately. · Avoid activities requiring mental alertness until you know how this medication affects you, as it may cause dizziness or blurred vision. · Do not stop taking this medication abruptly without consulting your healthcare provider. |